Potential of Glycyrrhiza in the prevention of colitis-associated colon cancer

被引:0
|
作者
Liu, Fang [1 ,2 ]
Gu, Zhili [2 ]
Yi, Feiyang [2 ]
Liu, Xue [2 ]
Zou, Wenxuan [2 ]
Xu, Qingxia [1 ]
Yuan, Yun [1 ]
Chen, Nianzhi [3 ]
Tang, Jianyuan [1 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610075, Peoples R China
[2] North Sichuan Med Coll, Nanchong, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 200000, Peoples R China
基金
中国博士后科学基金;
关键词
Glycyrrhiza; Colitis-associated Colon Cancer; Inflammatory Bowel Disease; Precancerous lesions; Dietary supplement; NF-KAPPA-B; COLORECTAL-CANCER; GLYCYRRHETINIC ACID; ULCERATIVE-COLITIS; SAFETY ASSESSMENT; INDUCED TOXICITY; GUT MICROBIOTA; CYCLE ARREST; UPLC-MS/MS; RAT PLASMA;
D O I
10.1016/j.fitote.2025.106398
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ethnopharmacological relevance: Glycyrrhiza, a legume native to the Mediterranean region, has a long history of ethnomedicinal use in China. Due to its antiviral, antibacterial, anti-inflammatory, antioxidant, antitumor, antiulcer, and hepatoprotective properties, Glycyrrhiza is widely utilized in the treatment of gastrointestinal disorders. The aim of the review: The specific mechanisms of the main active constituents of glycyrrhiza in the treatment of inflammatory bowel disease, precancerous lesions and colorectal cancer at all stages of the colitis-associated colon cancer "Inflammation-Dysplasia-Cancer" sequence, as well as its pharmacokinetics, toxicology, formulation improvements, and application studies, are reviewed to provide new insights and perspectives on glycyrrhiza as a dietary supplement to treat and prevent colitis-associated colon cancer. Materials and methods: Information on Glycyrrhiza was retrieved from electronic databases, including PubMed and Web of Science. Results: Glycyrrhiza is a well-established medicinal plant with significant potential for applications in both the food and pharmaceutical industries. Over 400 active constituents have been identified in Glycyrrhiza, including terpenoids, flavonoids, isoflavones, coumarins, and polyphenols. Numerous studies have demonstrated that Glycyrrhiza and its active compounds can inhibit the "Inflammation-Dysplasia-Cancer" progression of colitis associated colon cancer by mitigating inflammatory bowel disease, reducing the number of intestinal precan- cerous lesions, and counteracting colorectal cancer. Furthermore, derivatives and nanocarriers are crucial for the effective treatment of colitis-associated colon cancer using Glycyrrhiza and its active constituents. Conclusion: In conclusion, Glycyrrhiza is a plant with both medicinal and nutritional value, making it a potential food ingredient and dietary supplement for the treatment of colitis-associated colon cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Tussilagone Reduces Tumorigenesis by Diminishing Inflammation in Experimental Colitis-Associated Colon Cancer
    Nam, Sang-Hyeon
    Kim, Jin-Kyung
    BIOMEDICINES, 2020, 8 (04)
  • [42] Surveillance for colitis-associated colon neoplasia
    Hugh James Freeman
    World Journal of Gastroenterology, 2010, 16 (37) : 4646 - 4651
  • [43] Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen
    Beatty, Pamela
    Ranganathan, Sarangarajan
    Finn, Olivera J.
    ONCOIMMUNOLOGY, 2012, 1 (03) : 263 - 270
  • [44] Stat3: Friend or Foe in Colitis and Colitis-associated Cancer?
    Han, Jie
    Theiss, Arianne L.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : 2405 - 2411
  • [45] Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients
    Hata, Keisuke
    Kishikawa, Junko
    Anzai, Hiroyuki
    Shinagawa, Takahide
    Kazama, Shinsuke
    Ishii, Hiroaki
    Nozawa, Hiroaki
    Kawai, Kazushige
    Kiyomatsu, Tomomichi
    Tanaka, Junichiro
    Tanaka, Toshiaki
    Nishikawa, Takeshi
    Otani, Kensuke
    Yasuda, Koji
    Yamaguchi, Hironori
    Ishihara, Soichiro
    Sunami, Eiji
    Kitayama, Joji
    Watanabe, Toshiaki
    DIGESTIVE ENDOSCOPY, 2016, 28 (03) : 260 - 265
  • [46] Molecular Mechanisms and Clinical Aspects of Colitis-Associated Cancer in Ulcerative Colitis
    Yamamoto-Furusho, Jesus K.
    Gutierrez-Herrera, Fausto D.
    CELLS, 2025, 14 (03)
  • [47] Prevention of Colitis-associated Cancer: Natural Compounds that Target the IL-6 Soluble Receptor
    Moriasi, Cate
    Subramaniam, Dharmalingam
    Awasthi, Shanjana
    Ramalingam, Satish
    Anant, Shrikant
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (10) : 1221 - 1238
  • [48] Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer
    Gubatan, John
    Boye, Theresa Louise
    Temby, Michelle
    Sojwal, Raoul S.
    Holman, Derek R.
    Sinha, Sidhartha R.
    Rogalla, Stephan R.
    Nielsen, Ole Haagen
    MICROORGANISMS, 2022, 10 (07)
  • [49] Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice
    Jeon, Hee-Jin
    Yeom, Yiseul
    Kim, Yoo-Sun
    Kim, Eunju
    Shin, Jae-Ho
    Seok, Pu Reum
    Woo, Moon Jea
    Kim, Yuri
    NUTRITION RESEARCH AND PRACTICE, 2018, 12 (02) : 13 - 21
  • [50] DNA Methylation of MicroRNA-124a Is a Potential Risk Marker of Colitis-Associated Cancer in Patients with Ulcerative Colitis
    Ueda, Yuko
    Ando, Takayuki
    Nanjo, Sohachi
    Ushijima, Toshikazu
    Sugiyama, Toshiro
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (10) : 2444 - 2451